Pricing Log in Create free account

Regeneron Pharmaceuticals, Inc. (REGN) vs Royalty Pharma PLC (RPRX)

Regeneron Pharmaceuticals, Inc. and Royalty Pharma PLC are both Biotechnology companies. Regeneron Pharmaceuticals, Inc. is the larger, with a market value of $82.0B against $34.3B — 2.4× the size. Regeneron Pharmaceuticals, Inc. trades at the lower P/E: 18.9× against 42.3×. Royalty Pharma PLC grew revenue faster over the last twelve months: 10.0% against 9.29%. Royalty Pharma PLC has the higher net margin (32.0% vs 27.9%) and the lower return on invested capital (5.28% vs 9.34%). Both pay a dividend; Royalty Pharma PLC yields more (1.51% vs 0.47%). Across the 23 metrics below, Regeneron Pharmaceuticals, Inc. leads on 15 and Royalty Pharma PLC on 8.

Valuation

Metric REGN RPRX Biotechnology median
P/E 18.87 42.27 8.50
P/S 5.23 10.76 9.71
P/B 2.56 2.79 2.13
Price to free cash flow 22.74 20.82 20.82
EV/EBITDA 17.56 22.88 0.64
EV/Sales 4.94 13.96 9.21
Earnings yield 5.30% 2.37% (33.15%)
Free cash flow yield 4.40% 4.80% (25.50%)

Profitability

Metric REGN RPRX Biotechnology median
Gross margin 84.86% 100.00% 65.16%
Operating margin 24.74% 59.61% 0.00%
Net margin 27.86% 32.02% 0.00%
Free cash flow margin 23.01% 51.66% 0.00%
Return on equity 14.04% 8.42% (56.36%)
Return on assets 10.83% 4.26% (48.04%)
Return on invested capital 9.34% 5.28% 0.00%

Growth

Metric REGN RPRX Biotechnology median
Revenue growth (TTM) 9.29% 10.01% 6.02%
EPS growth (last fiscal year) 8.19% (5.52%) 30.26%
Revenue growth, 5-year CAGR 11.04% 2.30% 9.41%
Net income growth, 5-year CAGR 5.10% (4.59%) 0.00%

Health

Metric REGN RPRX Biotechnology median
Debt to equity 0.06 0.92 0.00
Current ratio 3.34 2.80 4.72
Net debt to EBITDA (1.43) 5.22 0.96

Dividend

Metric REGN RPRX Biotechnology median
Dividend yield 0.47% 1.51% 0.09%
Payout ratio 0.09 0.64 —

Size

Metric REGN RPRX Biotechnology median
Market cap 81.99b 34.28b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack